Clearance / Manifest 04
BPC-157 TB-500 Regulatory Status: FDA, WADA and the Research-Chemical Channel
The BPC-157 TB-500 regulatory status, read as a clearance ledger: neither constituent is an approved drug, both are on the WADA Prohibited List, both sit in FDA's 503A Category 2, and the blend ships through an unregulated channel.
The clearance ledger: where BPC-157 TB-500 stands
The BPC-157 TB-500 regulatory status is best read as a clearance ledger with no green lights. Neither component is approved by the FDA for human use, and the blend has no approved therapeutic indication anywhere [15]. Both constituents are on the World Anti-Doping Agency Prohibited List. And FDA has identified both as bulk drug substances that may present significant safety risks, placing each in "Category 2" for pharmacy compounding under section 503A — a status detailed on the Wolverine legal status and 503A compounding page [16].
Because neither peptide is an approved medicine, the material moves through unregulated research-chemical and veterinary-context channels. In that channel, product identity, purity, and the actual BPC-157:TB-500 ratio are not verified outside formal studies — which is why a regulatory page and a handling caveat end up describing the same problem from two directions [6].
WADA: both peptides are prohibited in sport
Both constituents of the blend are prohibited by the World Anti-Doping Agency. BPC-157 falls under the S0 non-approved-substances category — the catch-all for substances with no current approval for human therapeutic use by any government health authority. TB-500 / Thymosin Beta-4 falls under prohibited peptide, growth-factor, and tissue-repair categories [14]. The pairing is therefore banned in and out of competition for the relevant classes; combining them does not change either status.
The analytical infrastructure to enforce this is mature. Doping-control chemists synthesized and characterized the N-terminal acetylated 17-23 fragment of Thymosin Beta-4 — TB-500 itself — as a reference standard [15], and developed liquid-chromatography-mass-spectrometry methods to detect the parent peptide and its metabolites in equine plasma and urine at limits of detection around 0.01-0.02 ng/mL [14]. Those studies also anchor TB-500's chemical identity as Ac-LKKTETQ, distinct from the full-length protein.
FDA: not an approved drug, and flagged for compounding
Neither BPC-157 nor TB-500 is an FDA-approved drug. FDA approval of a finished drug is a separate question from whether a bulk substance may be used in compounding, and neither peptide clears either bar [16]. Under the Federal Food, Drug, and Cosmetic Act, a compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list [16].
FDA placed both BPC-157 and the Thymosin Beta-4 fragment (LKKTETQ, also known as TB-500) in Category 2 — bulk substances FDA identified as raising significant safety risks — effective with the September 29, 2023 update to the nominated-substances list [16]. Category 2 substances are not covered by FDA's enforcement-discretion policy for 503A compounding. The full mechanics of that status, and how legally compounded access works, are on the Wolverine legal status and 503A compounding page.